Phase 1 clinical study data on NRL-1049 shows dose-proportional increase in exposure and favorable safety profile SAN DIEGO, Nov. 6, 2025 /PRNewswire/ -- Neurelis, Inc., today announced it will ...
HARTFORD — Cities and towns should be allowed to create their own options for local taxation, as part of a comprehensive plan to reduce Connecticut’s “unsustainable” over-reliance on property taxes, ...
A growing body of preclinical research points to the TIE2 receptor and its angiopoietin ligands as a promising drug target for brain blood vessel defects, including arteriovenous malformations, venous ...
MT. LAUREL, N.J.--(BUSINESS WIRE)--Impulse Dynamics, Inc., a company dedicated to improving the lives of people with heart failure, today announced the first enrollment in a post-approval study of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results